JOEL LEWIS - 17 Nov 2025 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role
President and CEO, Director
Signature
Jack W. Callicutt, by power of attorney
Issuer symbol
GALT
Transactions as of
17 Nov 2025
Transactions value $
-$82,679
Form type
4
Filing time
19 Nov 2025, 16:01:27 UTC
Previous filing
12 Nov 2025
Next filing
19 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LEWIS JOEL President and CEO, Director C/O GALECTIN THERAPEUTICS INC., 4960 PEACHTREE INDUSTRIAL BLVD., STE 240, NORCROSS Jack W. Callicutt, by power of attorney 19 Nov 2025 0001725595

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GALT Common Stock Options Exercise $37.5K +15.7K +1.88% $2.39 848K 17 Nov 2025 Direct F1
transaction GALT Common Stock Sale -$94.6K -15.7K -1.85% $6.04 833K 17 Nov 2025 Direct F1, F4
transaction GALT Common Stock Options Exercise $16.2K +6.78K +0.81% $2.39 839K 18 Nov 2025 Direct F1
transaction GALT Common Stock Sale -$41.7K -6.78K -0.81% $6.15 833K 18 Nov 2025 Direct F1, F5
holding GALT Common Stock 2K 17 Nov 2025 as USTA custodian for a minor child F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GALT Stock option (right to buy) Options Exercise $0 -15.7K -69.8% $0.00 6.78K 17 Nov 2025 Common Stock 15.7K $2.39 Direct F1, F2
transaction GALT Stock option (right to buy) Options Exercise $0 -6.78K -100% $0.00 0 18 Nov 2025 Common Stock 6.78K $2.39 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.
F2 The options vested 100% on December 14, 2018.
F3 These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.
F4 The shares were sold in multiple transactions at prices ranging from $6.00 to $6.10. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F5 The shares were sold in multiple transactions at prices ranging from $6.00 to $6.32. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.